Resverlogix Corp.

300 4820 Richard Road SW
Calgary, Alberta T3E 6L1
Canada View Map >>

P: (403) 254-9252
F: (403) 256-8495
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET... more

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Contact People at this company

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Contact People at this company


Biotechnology, Drug Manufacturing & Research

Similar Companies

SemBioSys Genetics Inc., Medicago Inc., AEterna Zentaris Inc., Biomira Inc.

Stock Market


SIC Codes




Recently updated profiles at this company (48 contacts available)

Kenneth Lebioda
Senior Vice President Business and Corporate Development
Brad Cann
Chief Financial Officer
Ewelina Kulikowski
Vice President, Scientific Development
Clayton Paradis
Vice President, Investor Relations
Maria LaBrie
Office Manager
Sabine Schirm
Senior Clinical Research Associate, Consultant
Christopher Halliday
Manager, Corporate and Biomedical Development
Sarah Zapotichny
Director of Investor Relations and Corporate Communications
City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory